Incidence of intraocular pressure elevation following intravitreal ranibizumab (Lucentis) for age-related macular degeneration

Gustavo Msm Reis, John Grigg, Brian Chua, Anne Lee, Ridia Lim, Ralph Higgins, Alessandra Martins, Ivan Goldberg, Colin I. Clement

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: The aim of this article is to evaluate the rate of patients developing sustained elevated intraocular pressure (IOP) after ranibizumab (Lucentis) intravitreal (IVT) injections.

Design: This is a retrospective study.

Participants: Charts of 192 consecutive patients receiving Lucentis for age-related macular degeneration (AMD) were retrospectively reviewed.

Materials and methods: We enrolled patients with at least two IOP measurements between injections. Elevated IOP was defined as >21 mm Hg with an increase of at least 20% from baseline. Noninjected contralateral eyes of the same patient cohort were used as control.

Main outcome measures: Primary outcome was defined as elevated IOP. Secondary outcomes were presence and type of glaucoma, number of injections, and time to IOP elevation.

Results: Elevated IOP occurred at a significantly higher rate in eyes receiving IVT ranibizumab (7.47%; n = 9) compared with control (0.93%; n = 1). Patients with preexisting glaucoma or ocular hypertension (OHT) were more likely to develop elevated IOP after IVT ranibizumab injection.

Conclusion: Intravitreal ranibizumab injections are associated with sustained IOP elevation in some eyes.

Original languageEnglish
Pages (from-to)3-7
Number of pages5
JournalJournal of Current Glaucoma Practice
Volume11
Issue number1
DOIs
Publication statusPublished - 1 Feb 2017
Externally publishedYes

Keywords

  • age-related macular degeneration
  • intraocular pressure
  • ranibizumab

Fingerprint Dive into the research topics of 'Incidence of intraocular pressure elevation following intravitreal ranibizumab (Lucentis) for age-related macular degeneration'. Together they form a unique fingerprint.

Cite this